Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure)

JACC: Heart Failure

Volumn 4, Issue 7, 2016, Pages 539-547

  Wan, Siu Hin ^a   McKie, Paul M ^a   Schirger, John A ^a   Slusser, Joshua P ^a   Hodge, David O ^a   Redfield, Margaret M ^a   Burnett, John C ^a   Chen, Horng H ^a  

^a MAYO CLINIC   (United States)

Author keywords

B type natriuretic peptide; Cardiorenal syndrome; Diastolic dysfunction; Heart failure with preserved ejection fraction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; PLACEBO; SODIUM; THIAZIDE DIURETIC AGENT; NATRIURETIC FACTOR;

AGED; ARTHRALGIA; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIASTOLE; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ENDOCRINE FUNCTION TEST; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INJECTION SITE REACTION; KIDNEY FUNCTION TEST; MALE; MICTURITION; MITRAL VALVE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; TACHYPHYLAXIS; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION; ASYMPTOMATIC DISEASE; DIAGNOSTIC IMAGING; DIASTOLIC HEART FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY; PROOF OF CONCEPT; SUBCUTANEOUS DRUG ADMINISTRATION; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASYMPTOMATIC DISEASES; BLOOD FLOW VELOCITY; CYCLIC GMP; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, DIASTOLIC; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MITRAL VALVE; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PROOF OF CONCEPT STUDY; SODIUM; TACHYPHYLAXIS; TREATMENT OUTCOME;

EID: 84971440706     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.12.014     Document Type: Article

References (19)

1. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
2. Bursi F., Weston S.A., Redfield M.M., et al. Systolic and diastolic heart failure in the community. JAMA 2006, 296:2209-2216.
3. Wan S.H., Vogel M.W., Chen H.H. Pre-clinical diastolic dysfunction. J Am Coll Cardiol 2014, 63:407-416.
4. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.R., Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
5. Abhayaratna W.P., Marwick T.H., Smith W.T., Becker N.G. Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart 2006, 92:1259-1264.
6. Vogel M.W., Slusser J.P., Hodge D.O., Chen H.H. The natural history of preclinical diastolic dysfunction: a population-based study. Circ Heart Fail 2012, 5:144-151.
7. Lainchbury J.G., Burnett J.C., Meyer D., Redfield M.M. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 2000, 278:H33-H40.
8. Huntley B.K., Sandberg S.M., Noser J.A., et al. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol 2006, 209:943-949.
9. Stevens T.L., Burnett J.C., Kinoshita M., Matsuda Y., Redfield M.M. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 1995, 95:1101-1108.
10. McKie P.M., Schirger J.A., Costello-Boerrigter L.C., et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol 2011, 58:2095-2103.
11. Meguro S., Kawai T., Matsuhashi T., et al. Basal-supported oral therapy with sitagliptin counteracts rebound hyperglycemia caused by GLP-1 tachyphylaxis. Int J Endocrinol 2014, 2014:927317.
12. Nauck M.A., Kemmeries G., Holst J.J., Meier J.J. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011, 60:1561-1565.
13. Picard M.H., Adams D., Bierig S.M., et al. American Society of Echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr 2011, 24:1-10.
14. Shah A.M., Spurgeon H.A., Sollott S.J., Talo A., Lakatta E.G. 8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes. Circ Res 1994, 74:970-978.
15. Clarkson P.B., Wheeldon N.M., MacFadyen R.J., Pringle S.D., MacDonald T.M. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation 1996, 93:2037-2042.
16. Solomon S.D., Zile M., Pieske B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380:1387-1395.
17. Voors A.A., Gori M., Liu L.C., et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015, 17:510-517.
18. Kane G.C., Karon B.L., Mahoney D.W., et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011, 306:856-863.
19. Martin F.L., McKie P.M., Cataliotti A., et al. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol 2012, 302:R292-R299.